ProCE Banner Activity

Key Concepts in HCC Treatment: Transitioning Patients From Locoregional to Systemic Therapy

Clinical Thought
When should patients with HCC be transitioned from locoregional to systemic therapy to maximize therapeutic benefit? In this commentary, HCC expert Richard Finn, MD, provides his thoughts on this important question.

Released: October 20, 2020

Expiration: October 19, 2021

Share

Faculty

Richard S. Finn

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Genentech, a member of the Roche Group

Lilly

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard Finn, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, CStone, Eisai, Lilly, Merck, Pfizer, and Roche/Genentech.